已收盤 05-08 16:00:00 美东时间
-1.170
-0.52%
Foreign healthcare stocks are earning some of the market's strongest Quant conviction right now, with the top five names on this ranking all carrying scores above 4.19, a cluster of high-conviction si...
05-07 19:50
今日重点评级关注:Citizens:维持Avalo Therapeutics"跑赢大市"评级,目标价从52美元升至62美元;BTIG:维持Avalo Therapeutics"买入"评级,目标价从40美元升至58美元
05-07 12:37
Barclays analyst Etzer Darout maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $225 to $234.
05-06 23:16
U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group May 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, Lumentum Holdings and TransDigm Group, on Wednesday. HIGHLIGHTS * Advanced Micro Devices AMD.O : Ev
05-06 15:13
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Jazz Pharmaceuticals 2026年第一季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **总营收表现:** 2026年第一季度总营收达到11亿美元,同比增长超过19%,创下公司历史最高第一季度营收纪录。主要增长驱动力来自Xywav、Epidiolex、Midevo和Zepzelca等核心产品。 **各产品线营收:** - Xywav净销售额4.08亿美元,同比增长18% - Epidiolex净销售额2.50亿美元,同比增长15% - Midevo净销售额4,100万美元(2025年8月上市以来) - Zepze
05-06 12:33
On Tuesday, Jazz Pharmaceuticals (NASDAQ:JAZZ) discussed first-quarter financia...
05-06 05:52
华盛资讯5月6日讯,爵士制药公布2026财年Q1业绩,公司Q1营收10.69亿美元,同比增长19.0%,归母净利润2.93亿美元,扭亏为盈。
05-06 05:23
华盛资讯5月6日讯,爵士制药公布2026财年Q1业绩,公司Q1营收10.69亿美元,同比增长19.1%,归母净利润2.93亿美元,扭亏为盈。
05-06 05:13
Jazz Pharmaceuticals shares are trading higher after the company reported bette...
05-06 04:30
Jazz Pharmaceuticals (NASDAQ:JAZZ) affirms FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.250 billion-$4.500 billion vs $4.445 billion estimate.
05-06 04:18